Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth

Stock Track

Apr 13

REMEGEN's stock surged 5.09% during intraday trading on Monday, reflecting positive market reaction to significant company developments.

The biopharmaceutical company announced that the New Drug Application for its drug Disitamab Vedotin (RC48, brand name: Aidixi®) for the treatment of HER2-expressing urothelial carcinoma has been approved by China's National Medical Products Administration. This approval marks the fifth approved indication for Disitamab Vedotin in China, specifically for use in combination with Toripalimab for treating locally advanced or metastatic urothelial carcinoma with HER2 expression.

Additionally, REMEGEN reported that its 2025 operating revenue increased by 89.36% year-on-year, primarily driven by rapid sales growth of its core products Telitacicept and Disitamab Vedotin in the domestic market, along with a significant increase in technology licensing revenue from granting exclusive rights to develop and commercialize Telitacicept outside Greater China. The company's financial statements have been audited and received an unqualified opinion, confirming the accuracy of these results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140166703"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140166703\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140166703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140166703","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth","media":"Stock Track","content":"<p>REMEGEN's stock surged 5.09% during intraday trading on Monday, reflecting positive market reaction to significant company developments.</p><p>The biopharmaceutical company announced that the New Drug Application for its drug Disitamab Vedotin (RC48, brand name: Aidixi®) for the treatment of HER2-expressing urothelial carcinoma has been approved by China's National Medical Products Administration. This approval marks the fifth approved indication for Disitamab Vedotin in China, specifically for use in combination with Toripalimab for treating locally advanced or metastatic urothelial carcinoma with HER2 expression.</p><p>Additionally, REMEGEN reported that its 2025 operating revenue increased by 89.36% year-on-year, primarily driven by rapid sales growth of its core products Telitacicept and Disitamab Vedotin in the domestic market, along with a significant increase in technology licensing revenue from granting exclusive rights to develop and commercialize Telitacicept outside Greater China. The company's financial statements have been audited and received an unqualified opinion, confirming the accuracy of these results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-13 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock surged 5.09% during intraday trading on Monday, reflecting positive market reaction to significant company developments.</p><p>The biopharmaceutical company announced that the New Drug Application for its drug Disitamab Vedotin (RC48, brand name: Aidixi®) for the treatment of HER2-expressing urothelial carcinoma has been approved by China's National Medical Products Administration. This approval marks the fifth approved indication for Disitamab Vedotin in China, specifically for use in combination with Toripalimab for treating locally advanced or metastatic urothelial carcinoma with HER2 expression.</p><p>Additionally, REMEGEN reported that its 2025 operating revenue increased by 89.36% year-on-year, primarily driven by rapid sales growth of its core products Telitacicept and Disitamab Vedotin in the domestic market, along with a significant increase in technology licensing revenue from granting exclusive rights to develop and commercialize Telitacicept outside Greater China. The company's financial statements have been audited and received an unqualified opinion, confirming the accuracy of these results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1140166703","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140166703","pubTimestamp":1776045452,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock surged 5.09% during intraday trading on Monday, reflecting positive market reaction to significant company developments.The biopharmaceutical company announced that the New Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"股票赛道|新药获批及营收强劲增长REMEGEN盘中大涨5.09%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock surged 5.09% during intraday trading on Monday, reflecting positive market reaction to significant company developments.The biopharmaceutical company announced that the New Drug Application for its drug Disitamab Vedotin (RC48, brand name: Aidixi®) for the treatment of HER2-expressing urothelial carcinoma has been approved by China's National Medical Products Administration. This approval marks the fifth approved indication for Disitamab Vedotin in China, specifically for use in combination with Toripalimab for treating locally advanced or metastatic urothelial carcinoma with HER2 expression.Additionally, REMEGEN reported that its 2025 operating revenue increased by 89.36% year-on-year, primarily driven by rapid sales growth of its core products Telitacicept and Disitamab Vedotin in the domestic market, along with a significant increase in technology licensing revenue from granting exclusive rights to develop and commercialize Telitacicept outside Greater China. The company's financial statements have been audited and received an unqualified opinion, confirming the accuracy of these results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}